- Home
- FOUR vs TVTX Comparison
FOUR vs TVTX Comparison
Compare FOUR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOUR | TVTX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.3B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FOUR | TVTX |
|---|---|---|
| Price | $40.87 | $26.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 13 |
| Target Price | ★ $87.35 | $36.25 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | N/A |
| Revenue This Year | $24.90 | $44.62 |
| Revenue Next Year | $14.56 | $31.76 |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $41.65 | $12.91 |
| 52 Week High | $107.16 | $42.13 |
Technical Indicators
Market Signals| Indicator | FOUR | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 38.23 |
| Support Level | N/A | $22.32 |
| Resistance Level | $76.31 | $31.47 |
| Average True Range (ATR) | 2.13 | 1.07 |
| MACD | -0.21 | -0.05 |
| Stochastic Oscillator | 0.21 | 7.33 |
Price Performance
Historical ComparisonAbout FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.